172 related articles for article (PubMed ID: 10064173)
21. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
Schwid SR; Goodman AD; Mattson DH
Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.
Patti F; Penaherrera JN; Zieger L; Wicklein EM
BMC Neurol; 2021 Aug; 21(1):324. PubMed ID: 34425763
[TBL] [Abstract][Full Text] [Related]
23. Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?
Durelli L; Oggero A; Verdun E; Isoardo G; Ricci A; Barbero P; Bergamasco B
J Neurol Sci; 2000 Sep; 178(1):37-41. PubMed ID: 11018247
[TBL] [Abstract][Full Text] [Related]
24. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
Logan-Clubb L; Stacy M
J Neurosci Nurs; 1995 Dec; 27(6):344-7. PubMed ID: 8770778
[TBL] [Abstract][Full Text] [Related]
25. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
[TBL] [Abstract][Full Text] [Related]
26. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
Ebers GC; Traboulsee A; Li D; Langdon D; Reder AT; Goodin DS; Bogumil T; Beckmann K; Wolf C; Konieczny A;
J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):907-12. PubMed ID: 20562430
[TBL] [Abstract][Full Text] [Related]
27. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
[TBL] [Abstract][Full Text] [Related]
28. Interferon beta-1b treatment does not induce autoantibodies.
Polman CH; Kappos L; Dahlke F; Graf R; Beckmann K; Bogumil T; Pozzilli C; Thompson AJ;
Neurology; 2005 Mar; 64(6):996-1000. PubMed ID: 15781815
[TBL] [Abstract][Full Text] [Related]
29. Urinary myelin basic protein-like material in patients with multiple sclerosis during interferon beta-1b treatment.
Whitaker JN; Layton BA; Bartolucci AA; Mitchell GW; Bashir K; Goodwin J; Kachelhofer RD
Arch Neurol; 1999 Jun; 56(6):687-91. PubMed ID: 10369307
[TBL] [Abstract][Full Text] [Related]
30. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
31. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis.
Rotondi M; Oliviero A; Profice P; Mone CM; Biondi B; Del Buono A; Mazziotti G; Sinisi AM; Bellastella A; Carella C
J Endocrinol Invest; 1998 Dec; 21(11):748-52. PubMed ID: 9972674
[TBL] [Abstract][Full Text] [Related]
32. T-cell interleukin-6 receptor binding in interferon-beta-1b-treated multiple sclerosis patients.
Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
Eur J Neurol; 2000 Nov; 7(6):647-53. PubMed ID: 11136350
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
[TBL] [Abstract][Full Text] [Related]
34. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
Bitsch A; Bahner D; Wachter C; Elitok E; Bogumil T; Dressel A; Polak T; Tumani H; Weber F; Poser S; Kitze B
Acta Neurol Scand; 2004 Dec; 110(6):386-92. PubMed ID: 15527451
[TBL] [Abstract][Full Text] [Related]
35. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
36. The potential teratogenic effects of interferon beta-1a and interferon beta-1b on in vitro embryonic development.
Uçar I; Ertekin T; Nisari M; Ceylan D; Al Ö; Ülger H
Folia Morphol (Warsz); 2016; 75(2):257-263. PubMed ID: 26711647
[TBL] [Abstract][Full Text] [Related]
37. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b.
Cohen BA; Greenberger PA; Saini S
Allergy Asthma Proc; 1998; 19(2):85-8. PubMed ID: 9578917
[TBL] [Abstract][Full Text] [Related]
38. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.
Frisullo G; Calabrese M; Tortorella C; Paolicelli D; Ragonese P; Annovazzi P; Radaelli M; Malucchi S; Gallo A; Tomassini V; Nociti V; D'Onghia M; Lo Re V; Rodegher M; Solaro C; Gasperini C
Mult Scler; 2014 Aug; 20(9):1265-8. PubMed ID: 24515732
[TBL] [Abstract][Full Text] [Related]
39. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis.
Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
Arch Neurol; 1999 Feb; 56(2):217-22. PubMed ID: 10025427
[TBL] [Abstract][Full Text] [Related]
40. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
